528150
PARP Inhibitor VIII, PJ34
The PARP Inhibitor VIII, PJ34, also referenced under CAS 344458-15-7, controls the biological activity of PARP. This small molecule/inhibitor is primarily used for Cell Structure applications.
同義詞:
PARP Inhibitor VIII, PJ34
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C17H17N3O2 · xHCl
CAS號碼:
分子量：:
295.34 (free base basis)
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77
暫時無法取得訂價和供貨情況
推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
desiccated (hygroscopic)
protect from light
顏色
white
溶解度
water: 5 mg/mL
運輸包裝
ambient
儲存溫度
−20°C
SMILES 字串
Cl.[nH]1c2c(c3c([c]1=O)cccc3)cc(cc2)NC(=O)CN(C)C
InChI
1S/C17H17N3O2.ClH/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15;/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22);1H
InChI 密鑰
RURAZZMDMNRXMI-UHFFFAOYSA-N
一般說明
A cell-permeable, water-soluble phenanthridinone-derivative that acts as a potent inhibitor of poly(ADP-ribose) polymerase (PARP; EC50 = 20 nM). Shown to be about 10,000 times more potent than the prototypical PARP inhibitor, 3-Aminobenzamide (Cat. No. 165350 ; EC50 = 200 µM). Does not act as an antioxidant at higher concentrations (1 µM to 10 mM). Exhibits neuroprotection in in vivo and in vitro models of stroke. Also available as a 20 mM solution in H2O(Cat. No. 528151 ).
生化／生理作用
Cell permeable: yes
EC50 = 20 nM inhibiting poly(ADP-ribose) polymerase (PARP)
Primary Target
PARP
PARP
Product does not compete with ATP.
Reversible: no
包裝
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
其他說明
Abdelkarim, G.E., et al. 2001. Int. J. Mol. Med.7, 255.
Garcia-Soriano, F.G., et al. 2001. Nature Med. 7, 108.
Mabley, G.J., et al. 2001. Inflamm. Res.50, 561.
Garcia-Soriano, F.G., et al. 2001. Nature Med. 7, 108.
Mabley, G.J., et al. 2001. Inflamm. Res.50, 561.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Joelle C Boulos et al.
Acta pharmacologica Sinica, 44(11), 2265-2281 (2023-06-22)
The majority of blood malignancies is incurable and has unforeseeable remitting-relapsing paths in response to different treatments. Cynaropicrin, a natural sesquiterpene lactone from the edible parts of the artichoke plant, has gained increased attention as a chemotherapeutic agent. In this
Pablo Iglesias et al.
International journal of molecular sciences, 24(10) (2023-05-27)
In recent years, new therapies have been developed based on molecules that target molecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. PARP1 has emerged as
Shiori Kuraoka et al.
Molecular & cellular proteomics : MCP, 100153-100153 (2021-10-01)
Mass spectrometry-enabled ADP-ribosylation workflows are developing rapidly, providing researchers a variety of ADP-ribosylome enrichment strategies and mass spectrometric acquisition options. Despite the growth spurt in upstream technologies, systematic ADP-ribosyl (ADPr) peptide mass spectral annotation methods are lacking. HCD-dependent ADP-ribosylome studies
Han-Wei Liu et al.
Neuron, 111(10), 1609-1625 (2023-03-16)
Stroke prognosis is negatively associated with an elevation of serum bilirubin, but how bilirubin worsens outcomes remains mysterious. We report that post-, but not pre-, stroke bilirubin levels among inpatients scale with infarct volume. In mouse models, bilirubin increases neuronal
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
